Base de dados : LILACS
Pesquisa : D01.248.497.158.685.750.212 [Categoria DeCS]
Referências encontradas : 30 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3 ir para página          

  1 / 30 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1118972
Autor: SILVA, Nazaré Carneiro da; GONÇALVES, Suellen Ferreira; ARAÚJO, Luciana Silva de; KASPER, Aline Aparecida München; FONSECA, Amanda Luisa da; SARTORATTO, Adilson; CASTRO, Kelly Christina Ferreira; MORAES, Tânia Mara Pires; BARATTO, Leopoldo Clemente; VAROTTI, Fernando de Pilla; BARATA, Lauro Euclides Soares; MORAES, Waldiney Pires.
Título: In vitro and in vivo antimalarial activity of the volatile oil of Cyperus articulatus (Cyperaceae)
Fonte: Acta amaz;49(4):334-342, out. - dez. 2019.
Idioma: en.
Resumo: Malaria is a disease of global tropical distribution, being endemic in more than 90 countries and responsible for about 212 million cases worldwide in 2016. To date, the strategies used to eradicate this disease have been ineffective, without specific preventive measures such as vaccines. Currently, the existing therapeutic arsenal is limited and has become ineffective against the expansion of artemisinin-resistant Plasmodium, demonstrating the need for studies that would allow the development of new compounds against this disease. In this context, we studied the volatile oil obtained from rhizomes of Cyperus articulatus (VOCA), a plant species commonly found in the Amazon region and popularly used as a therapeutic alternative for the treatment of malaria, in order to confirm its potential as an antimalarial agent by in vitro and in vivo assays. We cultured Plasmodium falciparum W2 (chloroquine-resistant) and 3D7 (chloroquine-sensitive) strains in erythrocytes and exposed them to VOCA at different concentrations in 96-well microplates. In vivo antimalarial activity was tested in BALB/c mice inoculated with approximately 106 erythrocytes infected with Plasmodium berghei. VOCA showed a high antimalarial potential against the two P. falciparum strains, with IC50 = 1.21 µg mL-1 for W2 and 2.30 µg mL-1 for 3D7. VOCA also significantly reduced the parasitemia and anemia induced by P. berghei in mice. Our results confirmed the antimalarial potential of the volatile oil of Cyperus articulatus. (AU)
Descritores: Plasmodium berghei
Plasmodium falciparum
Cloroquina
Artemisininas
Malária
Responsável: BR6.1 - BCS - Biblioteca de Ciências da Saúde


  2 / 30 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Saúde Pública
Texto completo
Id: lil-662953
Autor: Durand, Salomón; Sihuincha, Moisés; Lachira, Arnaldo; Chaves, Jorge; Cabezas, César.
Título: Necesidad de vigilar la resistencia del P. falciparum al artesunato en el Perú / A need to monitor P. falciparum resistance to artesunate in Peru
Fonte: Rev. peru. med. exp. salud publica;29(4):579-580, oct.-dic. 2012. ilus, graf, mapas, tab.
Idioma: es.
Descritores: Antimaláricos/farmacologia
Artemisininas/farmacologia
Plasmodium falciparum/efeitos dos fármacos
-Artemisininas/uso terapêutico
Resistência a Medicamentos
Malária Falciparum/tratamento farmacológico
Peru
Limites: Humanos
Tipo de Publ: Carta
Revisão
Responsável: BR1.1 - BIREME


  3 / 30 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1056435
Autor: Zaki, Mohamed Samir Ahmed; Haidara, Mohamed A; Alghamd, Mansour A; Shati, Ayed A; Wares, Adnan; Eid, Refaat A.
Título: Protective effect of dietary vitamin E (alpha; Tocopherol) on artemisinin induced oxidative liver tissue damage in rats / Efecto protector de la vitamina E en la dieta (alfa; tocoferol) sobre el daño oxidativo del tejido hepático inducido por artemisinina en ratas
Fonte: Int. j. morphol;38(2):278-288, abr. 2020. graf.
Idioma: en.
Projeto: Khalid University.
Resumo: This experiment was designed to study the effects of oral administration of artemether which is the most rapid-acting class of antimalarial drugs and the possible protective effect of vitamin E taken with it on the liver of albino rats. A total of twenty-four adult male albino rats were used in this study and were divided into four groups. Group one served as a control and rats in group two exposed to oral intake of artemether daily for fifteen days. The third and fourth groups treated with artemether plus low and high doses of vitamin E respectively. At the end of the experiment, the rats were sacrificed, and the livers were obtained and processed for histological, biochemical and statistical studies. Histological study of the hepatocytes of rats exposed to artemether showed nearly complete disintegration of most cellular contents except few numbers of mitochondria and rough endoplasmic reticulum. Also, the cytoplasm of these cells had few lysosomes, many vacuoles and irregular nuclei with abnormal distribution of chromatin and were shown. The hepatic sinusoids were dilated and filled with blood and vacuoles and bile ductules were abnormal in its structure. Treatment with low and high doses of vitamin E in concomitant with artemether ameliorated the hepatic histopathological lesions and its parenchyma attained nearly normal structure. As far as biochemical changes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in rats treated with artemether were significantly elevated as compared to the control. Superoxide dismutase (SOD) and malondialdehyde (MDA) levels were significantly increased in the liver in rats treated with artemether. However, vitamin E ameliorated the rise in ALT and AST with decreased MDA concentration and levels of SOD as compared to the corresponding artemether group values. Results of the present suggest that artemether has a harmful and stressful effect on hepatic tissue and the treatment with vitamin E may alleviate this toxicity.

Este experimento fue diseñado para estudiar los efectos de la administración oral de arteméter, la clase de medicamentos antipalúdicos de acción rápida, y el posible efecto protector de la vitamina E en el hígado de ratas albinas. Se utilizaron un total de 24 ratas albinas machos adultas y se dividieron en cuatro grupos. El grupo uno sirvió como control y las ratas en el grupo dos recibieron la dosis oral de arteméter diariamente durante 15 días. Los grupos tres y cuatro fueron tratados con arteméter, más dosis bajas y altas de vitamina E, respectivamente. Al final del experimento, se sacrificaron las ratas y se obtuvieron y procesaron los hígados para estudios histológicos, bioquímicos y estadísticos. El estudio histológico de los hepatocitos de ratas expuestas a arteméter mostró una desintegración casi completa de la mayoría de los contenidos celulares, excepto algunos mitocondrias y retículo endoplásmico rugoso. Además, el citoplasma de estas células tenía pocos lisosomas, muchas vacuolas y núcleos irregulares con distribución anormal de cromatina. Los sinusoides hepáticos estaban dilatados y llenos de sangre y vacuolas, y los conductos biliares tenían una estructura anormal. El tratamiento con dosis bajas y altas de vitamina E en forma concomitante con arteméter mejoró las lesiones histopatológicas hepáticas y su parénquima alcanzó una estructura casi normal. En cuanto a los cambios bioquímicos, la alanina aminotransferasa (ALT) y la aspartato aminotransferasa (AST) en ratas tratadas con arteméter se elevaron significativamente en comparación con el control. Los niveles de superóxido dismutasa (SOD) y malondialdehído (MDA) aumentaron significativamente en el hígado en ratas tratadas con arteméter. Sin embargo, la vitamina E mejoró el aumento de ALT y AST con una disminución de la concentración de MDA y los niveles de SOD en comparación con los valores correspondientes del grupo de arteméter. Los resultados del presente estudio sugieren que el arteméter tiene un efecto dañino y estresante sobre el tejido hepático y el tratamiento con vitamina E puede aliviar esta toxicidad.
Descritores: Vitamina E/farmacologia
Artemisininas/toxicidade
Doença Hepática Crônica Induzida por Substâncias e Drogas/enzimologia
-Aspartato Aminotransferases/análise
Vitamina E/administração & dosagem
Microscopia Eletrônica de Transmissão
Alanina Transaminase/análise
Modelos Animais de Doenças
Fígado/efeitos dos fármacos
Antimaláricos/toxicidade
Limites: Animais
Masculino
Ratos
Responsável: CL1.1 - Biblioteca Central


  4 / 30 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Alecrim, Maria das Graças Costa
Texto completo
Id: biblio-1002690
Autor: Pinto, Raquel de Medeiros; Sampaio, Vanderson de Souza; de Melo, Gisely Cardoso; Alecrim, Maria das Graças Costa; Mattos, Karine; Perdomo, Renata Trentin; Cordeiro, Sabrine da Costa; Parente, Ana Flávia Alves; de Carvalho, Lídia Raquel; Mendes, Rinaldo Pôncio; Lacerda, Marcus Vinícius Guimarães; Monteiro, Wuelton Marcelo; Weber, Simone Schneider.
Título: Overview of artemisinin effectiveness during outset years of its implementation in the western Brazilian Amazon
Fonte: Mem. Inst. Oswaldo Cruz;114:e190075, 2019. tab, graf.
Idioma: en.
Projeto: CAPES; . RMP; . KM; . CAPES.
Resumo: BACKGROUND The elimination of malaria depends on the blocking of transmission and of an effective treatment. In Brazil, artemisinin therapy was introduced in 1991, and here we present a performance overview during implementation outset years. METHODS It is a retrospective cohort (1991 to 2002) of patients treated in a tertiary centre of Manaus, with positive microscopic diagnosis of Plasmodium falciparum malaria, under treatment with using injectable or rectal artemisinin derivatives, and followed over 35-days to evaluate parasite clearance, death and recurrence. FINDINGS This cohort outcome resulted 97.6% (1554/1593) of patients who completed the 35-day follow-up, 0.6% (10/1593) of death and 1.8% (29/1593) of follow-up loss. All patients that died and those that presented parasitaemia recurrence had pure P. falciparum infections and received monotherapy. Considering patients who completed 35-day treatment, 98.2% (1527/1554) presented asexual parasitaemia clearance until D4 and 1.8% (27/1554) between D5-D10. It is important to highlight that had no correlation between the five treatment schemes and the sexual parasite clearance. Finally, it is noteworthy that we were able to observe also gametocytes carriage during all follow-up (D0-D35). MAIN CONCLUSIONS Artemisinin derivatives remained effective in the treatment of falciparum malaria during first 12-years of use in north area of Brazil.
Descritores: Plasmodium falciparum
Artemisininas
-Resistência a Medicamentos
Controle de Doenças Transmissíveis
Estudos de Coortes
Limites: Humanos
Responsável: BR1.1 - BIREME


  5 / 30 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-839493
Autor: Ye, Xuan-Yi; Ling, Qing-Zhi; Chen, Shao-Jun.
Título: Identification of neprilysin as a potential target of arteannuin using computational drug repositioning
Fonte: Braz. J. Pharm. Sci. (Online);53(2):e16087, 2017. tab, graf.
Idioma: en.
Projeto: Zhejiang Provincial Natural Science Foundation of China; . Ningbo Municipal Natural Science Foundation; . Administration of Traditional Chinese Medicine of Zhejiang Province.
Resumo: ABSTRACT The discovery of arteannuin (qinghaosu) in the 20th Century was a major advance for medicine. Besides functioning as a malaria therapy, arteannuin is a pharmacological agent in a range of other diseases, but its mechanism of action remains obscure. In this study, the reverse docking server PharmMapper was used to identify potential targets of arteannuin. The results were checked using the chemical-protein interactome servers DRAR-CPI and DDI-CPI, and verified by AutoDock Vina. The results showed that neprilysin (also known as CD10), a common acute lymphoblastic leukaemia antigen, was the top disease-related target of arteannuin. The chemical-protein interactome and docking results agreed with those of PharmMapper, further implicating neprilysin as a potential target. Although experimental verification is required, this study provides guidance for future pharmacological investigations into novel clinical applications for arteannuin.
Descritores: Simulação por Computador/classificação
Neprilisina/farmacologia
Artemisininas/análise
-Reposicionamento de Medicamentos/estatística & dados numéricos
Responsável: BR1.1 - BIREME


  6 / 30 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-911265
Autor: Okunlola, A. I; Okunlola, C. K; Okani, C. O; Adewole, O. S; Ofusori, D. A; Komolafe, O. A; Ojo, S. K; Bejide, R. A; Ayoka, A. O; Ojewole, J. A. O.
Título: Histological studies on the retina and cerebellum of Wistar rats treated with ArteetherTM
Fonte: Braz. j. morphol. sci;31(1):28-32, 1/3/2014. ilus.
Idioma: en.
Resumo: Introduction: Arteether TM, a derivative of artemisinin, is among the recent drugs that have given renewed hope for combating malarial menace. The present study investigated the effects of arteetherTM on the histology of the retina and cerebellum of Wistar rats. Materials and Methods: Twenty adult albino Wistar rats weighing 150-200 g, were randomly divided into four groups (A, B, C and D) of five animals each and used for this study. Group A rats were given intramuscular (i.m.) arteetherTM (3 mg/kg b.w.) daily for 3 days. Group B rats were given i.m. arteetherTM (6 mg/kg b.w.) daily for 3 days. Group C rats were also given i. m. of arteetherTM (3 mg/kg b. w.) daily for 3 days, and the same dose was repeated at two-weekly intervals for 4 further weeks; while Group D rats which received normal saline (0.9 % w/v, 3 ml/kg b.w.), served as controls. At the end of the experiment, the rats were sacrificed by cervical dislocation. The retina and cerebellum were excised and processed routinely for histopathology changes, using haematoxylin and eosin stain (H & E), as well as Nissl stain. Results: Results obtained showed normal cellular components of the retina and cerebellum in all groups, and no cyto-pathological changes were observed. Conclusion: Thus, this study showed that under light microscopic examination, therapeutic doses of arteetherTM caused no significant cyto-pathologic changes in the retina and cerebellum of Wistar rats.(AU)
Descritores: Retina/anatomia & histologia
Cerebelo/anatomia & histologia
Artemisininas/farmacologia
Malária/prevenção & controle
-Técnicas Histológicas
Ratos Wistar
Limites: Animais
Ratos
Responsável: BR1.1 - BIREME


  7 / 30 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-906979
Autor: Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos.
Título: Desinvestimento do medicamento artemeter para o tratamento de Malária Grave / Disinvestment of the drug artemether for the treatment of Serious Malaria.
Fonte: Brasília; CONITEC; out. 2017. tab.
Idioma: pt.
Resumo: CONTEXTO: A malária é uma doença parasitária infecciosa aguda causada por protozoários do gênero Plasmodium e representa um grave problema de saúde pública. No Brasil, há três espécies associadas à malária em seres humanos: P. falciparum, P. vivax e P. malariae. O demandante solicitou o desinvestimento do medicamento artemeter 80 mg/ml, mantendo apenas o artesunato 60 mg/ml como opção de tratamento injetável com derivado de artemisinina para malária grave. A recomendação de retirada do artemeter fundamenta-se em orientação do guia de tratamento da Organização Mundial de Saúde (OMS), publicado em 2015, que orienta que o tratamento de adultos e crianças com malária grave (incluindo as gestantes em todos os trimestres e mulheres lactantes) deve ser feito, preferencialmente, com artesunato intravenoso ou intramuscular. TECNOLOGIA SOLICITADA PARA DESINVESTIMENTO: Artemeter 80 mg/ml.: Tratamento da malária grave. EVIDÊNCIAS CIENTÍFICAS: Com o objetivo de avaliar se artesunato injetável é uma melhor opção terapêutica que o artemeter injetável para o tratamento da malária grave, em termos de eficácia, efetividade e segurança, foram pesquisadas evidências científicas comparando os dois medicamentos. Foi selecionada uma revisão sistemática da Cochrane que mostrou que o risco de mortalidade por todas as causas foi significativamente menor com o artesunato do que com o artemeter. O artesunato reduziu o risco de hipoglicemia, como evento adverso aos tratamentos, em relação ao artemeter. Não houve diferenças significativas entre os tratamentos na resolução do coma, no tempo para clearance do parasita e no tempo para desaparecimento da febre. IMPACTO ORÇAMENTÁRIO: Embora o custo de tratamento com artesunato 60 mg/mL seja maior do que com o artemeter 80 mg/ml, o demandante informou que não vai aumentar a quantidade de artesunato comprada, visto que os casos de malária grave estão diminuindo. RECOMENDAÇÃO DA CONITEC: Pelo exposto, os membros do Plenário da CONITEC, presentes na 56ª reunião ordinária, deliberaram que o tema fosse submetido à consulta pública com recomendação preliminar favorável ao desinvestimento do artemeter para tratamento da malária grave. CONSULTA PÚBLICA: Foi recebida somente 1 contribuição sobre experiência de profissional de saúde que concordou totalmente com a recomendação da CONITEC. : Os membros da CONITEC deliberaram por recomendar a exclusão do medicamento artemeter para o tratamento de malária grave. DECISÃO: A Portaria nº 42, de 9 de outubro de 2017, tornou pública a decisão de excluir o medicamento artemeter para o tratamento de Malária Grave, no âmbito do Sistema Único de Saúde ­ SUS.(AU)
Descritores: Artemisininas/efeitos adversos
Artemisininas/uso terapêutico
Recall de Medicamento
Malária/tratamento farmacológico
-Brasil
Análise Custo-Benefício
Avaliação da Tecnologia Biomédica
Sistema Único de Saúde
Limites: Humanos
Tipo de Publ: Revisão
Relatório Técnico
Estudo de Avaliação
Responsável: BR1.1 - BIREME


  8 / 30 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-787558
Autor: Lobo, Lis; Sousa, Bruno de; Cabral, Lília; Cristiano, Maria LS; Nogueira, Fátima.
Título: Highly active ozonides selected against drug resistant malaria
Fonte: Mem. Inst. Oswaldo Cruz;111(7):450-453tab.
Idioma: en.
Projeto: CAPES; . FCT; . FCT.
Resumo: Ever increasing multi-drug resistance by Plasmodium falciparum is creating new challenges in malaria chemotherapy. In the absence of licensed vaccines, treatment and prevention of malaria is heavily dependent on drugs. Potency, range of activity, safety, low cost and ease of administration are crucial issues in the design and formulation of antimalarials. We have tested three synthetic ozonides NAC89, LC50 and LCD67 in vitro and in vivo against multidrug resistant Plasmodium. In vitro, LC50 was at least 10 times more efficient inhibiting P. falciparum multidrug resistant Dd2 strain than chloroquine and mefloquine and as efficient as artemisinin (ART), artesunate and dihydroartemisinin. All three ozonides showed high efficacy in clearing parasitaemia in mice, caused by multi-drug resistant Plasmodium chabaudi strains, by subcutaneous administration, demonstrating high efficacy in vivo against ART and artesunate resistant parasites.
Descritores: Antimaláricos/farmacologia
Malária Falciparum/parasitologia
Plasmodium falciparum/efeitos dos fármacos
-Artemisininas/farmacologia
Cloroquina/farmacologia
Modelos Animais de Doenças
Mefloquina/farmacologia
Camundongos
Parasitemia/tratamento farmacológico
Limites: Humanos
Animais
Feminino
Responsável: BR1.1 - BIREME


  9 / 30 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-774952
Autor: Zuluaga-Idarraga, Lina Marcela; Tamayo Perez, María-Eulalia; Aguirre-Acevedo, Daniel Camilo.
Título: Therapeutic efficacy of alternative primaquine regimens to standard treatment in preventing relapses by Plasmodium vivax: A systematic review and meta-analysis / Eficacia terapéutica de esquemas de Primaquina usados como alternativa al tratamiento estándar en la prevención de recaídas por Plasmodium vivax: Una revisión sistemática y meta-análisis
Fonte: Colomb. med;46(4):183-191, Oct.-Dec. 2015. tab.
Idioma: en.
Resumo: Objective: To compare efficacy and safety of primaquine regimens currently used to prevent relapses by P. vivax. Methods: A systematic review was carried out to identify clinical trials evaluating efficacy and safety to prevent malaria recurrences by P. vivax of primaquine regimen 0.5 mg/kg/day for 7 or 14 days compared to standard regimen of 0.25 mg/kg/day for 14 days. Efficacy of primaquine according to cumulative incidence of recurrences after 28 days was determined. The overall relative risk with fixed-effects meta-analysis was estimated. Results: For the regimen 0.5 mg/kg/day/7 days were identified 7 studies, which showed an incidence of recurrence between 0% and 20% with follow-up 60-210 days; only 4 studies comparing with the standard regimen 0.25 mg/kg/day/14 days and no difference in recurrences between both regimens (RR= 0.977, 95% CI= 0.670 to 1.423) were found. 3 clinical trials using regimen 0.5 mg/kg/day/14 days with an incidence of recurrences between 1.8% and 18.0% during 330-365 days were identified; only one study comparing with the standard regimen (RR= 0.846, 95% CI= 0.484 to 1.477). High risk of bias and differences in handling of included studies were found. Conclusion: Available evidence is insufficient to determine whether currently PQ regimens used as alternative rather than standard treatment have better efficacy and safety in preventing relapse of P. vivax. Clinical trials are required to guide changes in treatment regimen of malaria vivax.

Objetivo: Comparar la eficacia y seguridad de los esquemas de primaquina actualmente usados para prevenir las recaídas de malaria por P. vivax. Métodos: A través de una revisión sistemática se identificaron ensayos clínicos que evaluaran la eficacia y seguridad para prevenir recurrencias por P. vivax del régimen de primaquina 0.5 mg/Kg/día por 7 o 14 días comparado al régimen estándar de 0.25 mg/Kg/día por 14 días. Se determinó la eficacia de primaquina con la incidencia acumulada de recurrencias posterior a 28 días. Se estimó el riesgo relativo global con un meta-análisis de efectos fijos. Resultados: Se identificaron 7 ensayos clínicos para el régimen 0.5 mg/Kg/día/7 días que mostraron una incidencia de recurrencias entre 0% y 20% con un seguimiento de 60 a 210 días; solo 4 estudios compararon con el régimen estándar y no se encontraron diferencias en las recurrencias entre ambos esquemas (RR= 0.977; IC 95%= 0.670-1.423). Se identificaron tres ensayos clínicos que usaron el esquema 0.5 mg/Kg/día/14 días con una incidencia de recurrencias entre 1.8% y 18.0% para 330 a 365 días; solo un estudio comparó con el régimen estándar (RR= 0.846; IC 95%= 0.484-1.477). Se encontró alto riesgo de sesgo y diferencias en la conducción de los estudios incluidos. Conclusión: No hay suficiente evidencia para determinar si los regímenes de primaquina usados como alternativas al tratamiento estándar tienen mejor eficacia para prevenir las recaídas de P. vivax. Se requieren ensayos clínicos para orientar los cambios en el esquema de tratamiento de este tipo de malaria.
Descritores: Antimaláricos/uso terapêutico
Malária Vivax/prevenção & controle
Plasmodium vivax
Primaquina/uso terapêutico
Prevenção Secundária/métodos
-Artemisininas/uso terapêutico
Cloroquina/uso terapêutico
Esquema de Medicação
Recidiva
Limites: Humanos
Tipo de Publ: Metanálise
Research Support, Non-U.S. Gov't
Revisão
Responsável: CO332 - Facultad de Medicina


  10 / 30 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-745456
Autor: Villalva Rojas, Ofelia del Rosario.
Título: Comparación de las biodisponibilidades in vitro de Artesunato tabletas de diferentes procedências / Comparación de las bioavailability in vitro Artesunate tablets from different sources.
Fonte: Rio de Janeiro; s.n; 2014. 80 p. ilus, mapas, tab, graf.
Idioma: pt.
Tese: Apresentada a Escola Nacional de Saúde Pública Sergio Arouca para obtenção do grau de Mestre.
Resumo: En las décadas pasadas se incrementó los casos de malaria en los países de la cuenca amazónica, inclu-yendo la aparición de P. falciparum y la resistencia a los medicamentos de primera línea; Cloroquina y Sulfadoxina / Pirimetamina, adicionalmente en estudios recientes se reportaron deficiencias en la calidad de los medicamentos antimalaricos43. Por lo que Perú cambió su esquema de tratamiento para P. falcipa-rum no complicada: con Mefloquina más Artesunato en la selva y Sulfadoxina / Pirimetamina en la costa norte. En el esquema de tratamiento de Perú, se utiliza un medicamento genérico nacional (multifuente) que no ha demostrado ser intercambiable con el medicamento original, debido a que la regulación actual no ha implementado este requisito; aunque en la Ley 29459, ya se señale como parte de los requisitos del Registro Sanitario y que se espere entre en vigencia gradualmente. Objetivo: comparar las disponibilida-des in vitro de las tabletas de Artesunato usadas por la estrategia sanitaria de malaria en Perú, con las tabletas de Artesunato fabricadas en empresas precalificadas por la Organización Mundial de la Salud (OMS) en Brasil y Ghana. Metodología: para los ensayos de control de calidad y pruebas de cinética de disolución se utilizó la Farmacopea Non Standard de Los Estados Unidos, las guías de FDA y OMS...

Malaria cases have increased in the countries of the Amazon basin in the past decades, including the ap-pearance of P. falciparum and resistance to first-line drugs; Chloroquine and Sulfadoxine / Pyrimethamine. In recent studies were reported deficiencies in the quality of antimalarial drugs, because of that Peru changed the treatment scheme for uncomplicated P. falciparum, and begin to use Mefloquine plus Arte-sunate for Amazon Area and Sulfadoxine / Pyrimethamine on the North coast. In Peruvian treatment scheme, is used a national generic drug (multisource), which one did not demonstrate to be interchangea-ble with the innovator, because, this is not yet a requirement to get the Sanitary Register, according to Law 29459, and hopefully it will be implemented gradually. Objective: compare the in vitro availability of Artesunate tablets used by the health strategy against malaria in Peru, with Artesunate tablets manufac-tured by WHO prequalified manufactures from Brazil and Ghana. Methodology: testing and dissolution kinetics tests were performed with Non Standard Pharmacopoeia of the United States, FDA and WHO guidelines...
Descritores: Antimaláricos
Artemisininas/uso terapêutico
Malária
Farmacocinética
Limites: Humanos
Responsável: BR526.1 - Biblioteca de Saúde Pública



página 1 de 3 ir para página          
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde